PAPER Azmi H
SEARCH RESULTS
19319 RESULTS
PAPER Lohr KM, Frost B, Scherzer C, Feany MB
Biotin rescues mitochondrial dysfunction and neurotoxicity in a tauopathy model.
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33608-33618. Epub 2020 Dec 14 PubMed: 33318181PAPER Wu D, Wang C, Pang P, Kong H, Lin Z, Wang H, Chen X, Zhao J, Hao Z, Zhang T, Guo X
The association between herpes simplex virus type 1 infection and Alzheimer's disease.
J Clin Neurosci. 2020 Dec;82(Pt A):63-70. Epub 2020 Nov 8 PubMed: 33317741PAPER Chidambaram H, Chinnathambi S
Role of cysteines in accelerating Tau filament formation.
J Biomol Struct Dyn. 2020 Dec 15;:1-10. PubMed: 33317395PAPER Wong LR, Wong P, Ho PC
Metabolic Profiling of Female Tg2576 Mouse Brains Provides Novel Evidence Supporting Intranasal Low-Dose Pioglitazone for Long-Term Treatment at an Early Stage of Alzheimer's Disease.
Biomedicines. 2020 Dec 9;8(12) PubMed: 33317213PAPER Biechele G, Franzmeier N, Blume T, Ewers M, Luque JM, Eckenweber F, Sacher C, Beyer L, Ruch-Rubinstein F, Lindner S, Gildehaus FJ, von Ungern-Sternberg B, Cumming P, Bartenstein P, Rominger A, Höglinger GU, Herms J, Brendel M
Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases.
J Neuroinflammation. 2020 Dec 14;17(1):374. PubMed: 33317543PAPER Kwakowsky A, Waldvogel HJ, Faull RL
The effects of amyloid-beta on hippocampal glutamatergic receptor and transporter expression.
Neural Regen Res. 2021 Jul;16(7):1399-1401. PubMed: 33318426PAPER Liu S, Gan J, Hu W, Wang XD, Zhu H, Du X, Shi Z, Huang G, Ji Y
The clinical characteristics and subtypes of patients with cognitive impairment in memory clinic.
J Clin Neurosci. 2020 Dec;82(Pt A):186-191. Epub 2020 Nov 20 PubMed: 33317730PAPER Lee J
Effects of Aerobic and Resistance Exercise Interventions on Cognitive and Physiologic Adaptations for Older Adults with Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Randomized Control Trials.
Int J Environ Res Public Health. 2020 Dec 9;17(24) PubMed: 33317169Stefan Lichtenthaler on New Data from Past BACE Inhibitor Trials Shed Light on Side Effects
COMMENT I congratulate both companies on sharing more detailed data from the terminated trials and on their collaborative effort to compare two trials and inhibitors. This is very important to better understand the effects, but also the side effects, of BACE inhi
Jochen Herms on BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
COMMENT This is a detailed analysis of the effect of the BACE inhibitor verubecestat on brain volume. I don’t understand why the authors did not consider with a single word that several preclinical studies have previously shown that certain BACE inhibitors acutel
Colin Masters on New Data from Past BACE Inhibitor Trials Shed Light on Side Effects
COMMENT The BACE 1 inhibitors are a powerful and specific class of drugs. They were used at very high doses, aiming for 70-90 percent inhibition of APP processing (as were the γ-secretase inhibitors). With the benefit of hindsight, we should not be surprised that
New Data from Past BACE Inhibitor Trials Shed Light on Side Effects
RESEARCH NEWS 2020-12-16 Research News BACE inhibitors succeeded in stemming the tide of Aβ production in the brain, but the drugs also slightly dulled cognition and shrank the brain, bringing the trials to a screeching halt. Rather than washing their hands of a failure and movin
PAPER Pompéia S, Rusted JM, Curran HV
Verbal fluency facilitated by the cholinergic blocker, scopolamine.
Hum Psychopharmacol. 2002 Jan;17(1):51-9. PubMed: 12404707Pat Kohlfeld
Current Filters
- Date Range : Feb 2020 to Feb 2021 x